FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Jun Yan(The University of Texas MD Anderson Cancer Center), Shulin Li(The University of Texas MD Anderson Cancer Center)

Nature Communications

January 25, 2019

10.1038/s41467-018-08271-x

Cited by 119

Related Papers

EMT, CTCs and CSCs in tumor relapse and drug-resistance

|Oncotarget|2015|464

Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients

|Scientific Reports|2016|195

IL6‐mediated inflammatory loop reprograms normal to epithelial‐mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta–deficient β2‐spectrin+/− mice

|Hepatology|2016|66

WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

|Nature Communications|2021|56

Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells

|Cell Communication and Signaling|2015|54